| Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report. P Horby, WS Lim, JR Emberson, M Mafham, JL Bell, L Linsell, N Staplin, ... The New England journal of medicine, 2020 | 9761* | 2020 |
| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5648 | 2021 |
| Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study AB Docherty, EM Harrison, CA Green, HE Hardwick, R Pius, L Norman, ... bmj 369, 2020 | 3562 | 2020 |
| Dexamethasone in hospitalized patients with Covid-19 RECOVERY Collaborative Group New England Journal of Medicine 384 (8), 693-704, 2021 | 2955 | 2021 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1765 | 2020 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 1614 | 2021 |
| Effect of hydroxychloroquine in hospitalized patients with Covid-19 RECOVERY Collaborative Group New England Journal of Medicine 383 (21), 2030-2040, 2020 | 1517 | 2020 |
| Genetic mechanisms of critical illness in COVID-19 E Pairo-Castineira, S Clohisey, L Klaric, AD Bretherick, K Rawlik, D Pasko, ... Nature 591 (7848), 92-98, 2021 | 1420 | 2021 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1403 | 2021 |
| Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 Y Peng, AJ Mentzer, G Liu, X Yao, Z Yin, D Dong, W Dejnirattisai, ... Nature immunology 21 (11), 1336-1345, 2020 | 1273 | 2020 |
| Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection S Feng, DJ Phillips, T White, H Sayal, PK Aley, S Bibi, C Dold, M Fuskova, ... Nature medicine 27 (11), 2032-2040, 2021 | 1153 | 2021 |
| Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score SR Knight, A Ho, R Pius, I Buchan, G Carson, TM Drake, J Dunning, ... bmj 370, 2020 | 1094 | 2020 |
| Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score SR Knight, A Ho, R Pius, I Buchan, G Carson, TM Drake, J Dunning, ... bmj 370, 2020 | 1094 | 2020 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 982 | 2022 |
| Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial PW Horby, M Mafham, JL Bell, L Linsell, N Staplin, J Emberson, ... The Lancet 396 (10259), 1345-1352, 2020 | 833 | 2020 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 809 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 765 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 765 | 2021 |
| Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study OV Swann, KA Holden, L Turtle, L Pollock, CJ Fairfield, TM Drake, S Seth, ... bmj 370, 2020 | 743 | 2020 |
| Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre … APS Munro, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, M Bula, ... The Lancet 398 (10318), 2258-2276, 2021 | 737 | 2021 |
